919110-26-2

Upstream product

• 919110-21-7 (4-((4-((5-chloro-1-phenylsulfonyl-1H-indol-2-yl)-sulfonyl)-2-oxopiperazin-1-yl)-methyl)-phenyl)-boronic acid 
• 919110-20-6 (4-(2-oxopiperazin-1-ylmethyl)-phenyl)boronic acid hydrochloride 
• 919110-17-1 4-(4-iodobenzyl)-3-oxopiperazine-1-carboxylic acid tert-butyl ester 
• 249292-35-1 5-chloro-1-phenyl-sulfonylindole-2-sulfonyl chloride 
• 919110-24-0 (2-(3-chloro-6-oxo-6H-pyridazin-1-yl)ethyl)-methylcarbamic acid tert-butyl ester 
• 919110-25-1 N-((5-chloro-1H-indol-2-yl)-sulfonyl)-N-(2-((4-dihydroxyborylbenzyl)amino)ethyl)glycine 

Downstream Products

• 919110-27-3 (2-(3-(4-(4-(5-chloro-1H-indole-2-sulfonyl)-2-oxopiperazin-1-ylmethyl)phenyl)-6-oxo-6H-pyridazin-1-yl)ethyl)methylcarbamic acid tert-butyl ester 

Relevant academic research and scientific papers

HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA

The invention relates to compounds of formula (I), Chemical formula should be inserted here. Please see paper copy wherein R1 is hydrogen, C1-3alkyl, R5R6 aminoC1-5alkyl, where R5 and R6 are each independently selected from hydrogen and C1-3alkyl, or R5 and R6 may, together with the nitrogen to which they are attached, form a five- or six-membered heterocyclic ring, where said heterocyclic ring has 0 or 1 additional heteroatom; n is 1 or 2; each R2 are independently selected from hydrogen, oxo and C1-3alkyl, R3 is an indolyl, and R4 a hydrogen or a halogen; or a pharmaceutically acceptable salt thereof, said compounds possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the compounds, to their use, to pharmaceutical compositions comprising them, to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect, and to combinations comprising them.